GSK's revenues top £30bn as vaccine and cancer drug sales soar
GSK's annual vaccine sales surged by 25%, driven by Shingrix and Arexvy. Cancer drugs also performed strongly.
Stay updated with breaking news from While Astrazeneca. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GSK's annual vaccine sales surged by 25%, driven by Shingrix and Arexvy. Cancer drugs also performed strongly.
The FDA will decide this summer which strains the next Covid-19 vaccines should address. But companies are also taking a longer view, developing shots for the future that offer different features than the current ones and potentially broader protection against a wider range of pathogens.
Among the companies with reports and trading updates today are Unilever, British American Tobacco, AstraZeneca, Bellway, Compass Group and Redrow.
The first authorized drugs and vaccines indicated for COVID-19 generated more than a combined $10.91 billion in sales during the first quarter of 2021—more than double the $4.23 billion generated all of 2020. This list contains the Top 8 Best-Selling COVID-19 Vaccines and Drugs of Q1 2021
But while all the seven vaccines boosted spike protein immunogenicity after two doses of AstraZeneca, in case of Pfizer, after two doses, a booster dose of Valneva was not found to be effective.